BioRestorative Therapies in the Spotlight
BioRestorative Therapies, Inc. (NASDAQ: BRTX), a clinical stage innovator in regenerative medicine, is poised to discuss significant advancements at the Benzinga All-Access Show. Lance Alstodt, the CEO of BioRestorative, is set to share insights regarding the promising clinical data surrounding their groundbreaking product, BRTX-100, during his interview.
Details of the Benzinga All-Access Show
During the Benzinga All-Access Show, scheduled for June 18, 2025, at 10:50 a.m. Eastern Time, the audience will gain valuable information about BioRestorative’s latest initiatives. This appearance underscores the company's ongoing commitment to transparency and engagement with its stakeholders.
Watch the Live Webcast
The interview will be accessible via a live webcast, allowing viewers to engage with the discussion surrounding BioRestorative's advancements. Those interested can look forward to an informative session full of insights into the company's future.
About BRTX-100 and Its Applications
BRTX-100 is pivotal to BioRestorative’s mission, harnessing the power of innovative stem cell therapies. This product, derived from the patient's own mesenchymal stem cells, aims to offer a non-surgical approach to treating painful lumbosacral disc disorders.
Clinical Trials and Regulatory Approvals
BioRestorative is advancing through clinical trials with BRTX-100 as it targets chronic lower back pain due to degenerative disc disease. Importantly, they have also received Investigational New Drug (IND) clearance from the FDA to study this product in treating chronic cervical discogenic pain, signaling the product’s potential to revolutionize pain management.
The Metabolic Program: A New Frontier
In addition to addressing disc and spine disorders, BioRestorative is exploring therapeutic candidates under its metabolic program, ThermoStem. This initiative focuses on utilizing brown adipose tissue-derived stem cells to combat obesity and metabolic disease. Early research points towards the ability of these therapies to enhance metabolic regulation in humans.
BioCosmeceuticals Offering
BioRestorative also operates a BioCosmeceutical platform, which showcases the company’s versatility in the regenerative medicine space. Their current products aim to reduce the visible signs of aging using secretome technologies, and future developments may expand this product line even further.
Looking Ahead
BioRestorative’s ongoing clinical projects highlight its dedication to improving patient quality of life through innovative therapies. As the company shares its developments during the Benzinga All-Access Show, stakeholders and viewers alike will gain a deeper understanding of the significant impact these advancements could have on the healthcare landscape.
Frequently Asked Questions
What is BRTX-100 used for?
BRTX-100 is designed for the non-surgical treatment of painful lumbosacral disc disorders and chronic lower back pain.
When and where can I watch the Benzinga interview?
The interview will take place on June 18, 2025, at 10:50 a.m. Eastern Time, available via a live webcast.
Who is the CEO of BioRestorative?
Lance Alstodt is the Chief Executive Officer of BioRestorative Therapies, Inc.
What are BioRestorative's main research focuses?
BioRestorative focuses on regenerative medicine aimed at cell therapies for disc/spine disease and metabolic disorders.
How can I learn more about BioRestorative's products?
For more information, visit the official BioRestorative Therapies website, where updates and details about their products are available.